Day: March 20, 2025

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. “2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “In March 2024, we acquired AVTX-009, a promising monoclonal antibody targeting interleukin-1β....

AUCATZYL® (obecabtagene autoleucel) U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024 Obe-cel MHRA and EMA marketing authorizations expected in H2 2025 Initial six patients dosed in Phase 1 dose confirmation trial in Systemic Lupus Erythematosus (SLE) Company to provide clinical development program updates, including plans for expansion in autoimmune diseases, at R&D investor event to be held on April 23rd Conference call to be held today at 08:30 am EDT/12:30 pm GMT: conference call participants should pre-register using the link at the bottom of this press releaseLONDON, March 20, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering...

Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; deprioritizing further expansion arms in SCLC, NSCLC and NE tumors MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β...

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseases Highly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third quarter of 2025 Proprietary SNAP-TI platform promoting antigen-specific immune tolerance is anticipated to drive multiple future pipeline and partnership opportunities Strategic prioritization of resources expected to provide a cash runway into 2027OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), an immunology and inflammation (I&I) company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results...

DUBLIN and SHANGHAI, March 20, 2025 (GLOBE NEWSWIRE) — PDD Holdings Inc. (“PDD Holdings” or the “Company”) (NASDAQ: PDD), today announced its unaudited financial results for the fourth quarter ended and the fiscal year ended December 31, 2024. Fourth Quarter 2024 HighlightsTotal revenues in the quarter were RMB110,610.1 million (US$115,153.5 million), an increase of 24% from RMB88,881.0 million in the same quarter of 2023.Operating profit in the quarter was RMB25,592.2 million (US$3,506.1 million), an increase of 14% from RMB22,395.0 million in the same quarter of 2023. Non-GAAP2 operating profit in the quarter was RMB27,996.5 million (US$3,835.5 million), an increase of 14% from RMB24,579.9 million in the same quarter of 2023.Net income attributable to ordinary shareholders in the quarter was RMB27,446.6 million (US$3,760.2...

– Achieved Approximately $304 Million of Inventory Reduction in the Fiscal Fourth Quarter, Bringing Total Inventory Reduction Since Fiscal Second Quarter Peak to $419 Million – – Service Revenue Increased 14.5% , or 7.1% on a Same-store Basis, for the Full Year Fiscal 2025 – – Provides Fiscal 2026 Modeling Assumptions – WEST FARGO, N.D., March 20, 2025 (GLOBE NEWSWIRE) — Titan Machinery Inc. (Nasdaq: TITN), a leading network of full-service agricultural and construction equipment stores, today reported financial results for the fiscal fourth quarter and full year ended January 31, 2025. “Our fiscal fourth quarter results reflect a significant step forward in the execution of our inventory reduction initiative, particularly in our domestic Agriculture segment. We reduced inventory by approximately...

Fourth quarter Gross margin increased approximately 760 basis points compared to fiscal 2023All fourth quarter profitability measures improved when compared to fiscal 2023Reduced inventory for the eighth consecutive quarter DODGEVILLE, Wis., March 20, 2025 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) (“Lands’ End” or the “Company”) today announced financial results for the fourth quarter and full year of fiscal 2024 ended January 31, 2025. Andrew McLean, Chief Executive Officer, stated, “Lands’ End had a strong finish to a year defined by continued positive momentum across the business. We increased gross profit dollars, expanded gross margins and grew GMV each quarter of fiscal 2024, excluding the 53rd week, resulting in a return to profitability for the full year. Through our amazing products, robust product franchises and...

Division reaches document stacking milestone with AI-Powered technology solution.Origence Lending ServicesOrigence Lending Services served 360,000 members and grew to 167 credit unions in 2024.Irvine, California, March 20, 2025 (GLOBE NEWSWIRE) — Origence Lending Services, a division of Origence, served 360,000 credit union members and grew to 167 credit unions funding $5 billion in 2024.  The division also marked a significant milestone in document management, stacking, and processing more than 30 million documents since its launch of an advanced AI-powered solution in 2023. These numbers highlight another successful year of continued growth, providing scalable outsourced solutions designed to improve efficiencies and streamline operations for credit unions. Origence Lending Services operates 24 hours a day, 7 days...